profit from every $100 of sales.
$0$100
Cadrenal Therapeutics
$1.37+39.80% today
-88.7% in 1 year
1-year low $0.871-year high $12.35
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Cadrenal Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2023 to $0 in 2025, with -$13.2 million of profit last year.
SalesProfit
Cadrenal Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Cadrenal Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Cadrenal Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| 0 | 0 | 0 | |
| – | – | – | |
| -8 | -11 | -13 | |
| -8 | -11 | -13 | |
| -8 | -11 | -13 | |
| -9.29 | -8.73 | -6.64 | |
| – | – | – | |
| – | – | – | |
| – | – | – |
Balance sheet
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total assets | 9 | 10 | 4 |
| Cash | 8 | 10 | 4 |
| Total debt | 0 | 0 | – |
| Total liabilities | 1 | 3 | 2 |
| 8 | 7 | 3 | |
| 1 | 1 | 2 | |
| -85.4% | -116.4% | -388.3% | |
| -108.6% | -143.2% | -483.3% |
Cash flow
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| -4 | -7 | -13 | |
| 0 | 0 | 0 | |
| -4 | -7 | -13 | |
| Dividends paid | – | – | – |
| – | 0 | 0 | |
| 1 | 1 | 2 |
Valuation
- –
- –
- –
- 8.2×
- –
- –
- –
- -296.9%
- -311.8%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -670.4%
- -149.5%
- -411.0%
- -415.4%
- -670.4%
- –
Growth
- –
- –
- −71.1%
- –
- +37.0%
Financial health
- -0.2×
- 0.00
- 0.0%
- –
- 2.68
- 2.68
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 21%of 871
What analysts expect
- Average price target
- $32.00
- Range
- $32.00 – $32.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -1.04 | -1.51 | +31.1% |
| Mar 31, 2026 | -1.41 | -1.17 | −20.5% |
| Nov 10, 2025 | -1.31 | -1.55 | +15.5% |
| Aug 11, 2025 | -1.87 | -1.60 | −16.9% |
| May 8, 2025 | -2.09 | -1.64 | −27.4% |
| Mar 13, 2025 | -2.74 | -1.71 | −60.2% |
| Nov 7, 2024 | -2.18 | -1.83 | −19.1% |
| Aug 7, 2024 | -2.25 | -19.04 | +88.2% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
39No pass
Benjamin Graham
40No pass
Philip Fisher
34No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
30No pass
Terry Smith
30No pass
Questions about Cadrenal Therapeutics
Is Cadrenal Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Cadrenal Therapeutics AI analysis
What does Cadrenal Therapeutics do?
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. It is in Biotechnology.
Does Cadrenal Therapeutics pay a dividend?
No. Cadrenal Therapeutics does not pay a dividend at the moment; in 2025 it returned $291,883 to shareholders by buying back its own shares.
Is Cadrenal Therapeutics stock halal?
No. Cadrenal Therapeutics does not pass our halal screen: its cash and confirmed interest-bearing investments are 94% of its market value, at or above the 33% limit. How we check
How has Cadrenal Therapeutics stock done over the past year?
Down 88.7% over the past twelve months, to $1.37. It traded between $0.87 and $12.35 and is 88.9% below its high.
Who are Cadrenal Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Cadrenal Therapeutics's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.